Back Other Health News

Other Infections

ICAAC 2014: Antibiotic Stewardship Programs Reduce Use and Improve Outcomes

Programs to promote appropriate use of antibiotics in hospitals and other healthcare facilities can help reduce use of these drugs and thereby ameliorate the risk of developing resistance, researchers reported at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy last week in Washington, DC.

alt

Read more:

ICAAC 2014: Delafloxacin Shows Promise as a Single-dose Treatment for Gonorrhea

A new antibiotic, delafloxacin, demonstrated potent activity against gonorrhea -- including drug-resistant strains -- in a laboratory study, and its pharmacokinetics suggest that single-dose oral treatment will be feasible, according to research presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy this week in Washington, DC.

alt

Read more:

AIDS 2014: Novel PaMZ Tuberculosis Regimen Could Reduce Treatment Duration

A novel tuberculosis (TB) drug regimen could treat drug-sensitive and some forms of drug-resistant TB far more quickly than current standard therapy, according to findings from a Phase 2b trial presented today at the 20th International AIDS Conference (AIDS 2104) in Melbourne, Australia.

alt

Read more:

ICAAC 2014: Single Dose of Flu Drug Peramavir Looks Safe and Effective

A single dose of the investigational neuraminidase inhibitorperamavir (Rapivab) administered within 2 days after symptom onset lowered influenza viral load and reduced duration of symptoms including fever, according to study findings presented at the the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy this week in Washington, DC.

alt

Read more:

WHO Announces Plan to Eliminate Tuberculosis in Low-incidence Countries

The World Health Organization (WHO) and the European Respiratory Society (ERS) last week introduced a new framework for the elimination of tuberculosis (TB) in more than 30 low-incidence countries, which includes most of Western Europe, the U.S., Canada, and Australia.

alt

Read more:

ICAAC 2014: Attempt to Shorten Standard Tuberculosis Treatment Fails in REMoxTB Trial

Two 4-month treatment regimens containing moxifloxacin were less effective than the standard 6-month regimen for drug-sensitive tuberculosis (TB), even though they produced a more rapid decline in bacterial load, according to results from the REMoxTB trial, which were presented in a poster session at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy this week in Washington, DC, and published simultaneously in the September 7 New England Journal of Medicine.

alt

Read more:

STD Prevention Conference: Drug-resistant Gonorrhea Rates Plummet in U.S.

Preliminary results announced at the U.S. 2014 STD Prevention Conference last week in Atlanta have shown that the proportion of cases of gonorrhea that are drug-resistant has fallen since 2011, with a sharp decline between 2012 and 2013. The fall is particularly marked among gay and other men who have sex with men (MSM), who had had the highest rates of drug-resistant gonorrhea.
alt

Read more:

AIDS 2014: Young People with HIV Respond Well to Human Papillomavirus Vaccine

The quadrivalent human papillomavirus (HPV) vaccine worked as well for teens and young adults with HIV as it did for their HIV negative counterparts, according to study findings presented the 20thInternational AIDS Conference last week in Melbourne.

alt

Read more:

Delamanid for Tuberculosis Approved in Europe, New Drugs Under Study

The European Union recently approved the new anti-tuberculosis drug delamanid (Deltyba) for use in combination therapy for people with multidrug-resistant TB. In related news, the Stop TB Partnership announced that it will make another new drug, bedaquiline (Sirturo), available in more than 100 low- and middle-income countries.

alt

Read more: